NASDAQ:TRVN Trevena (TRVN) Stock Forecast, Price & News $1.14 -0.02 (-1.72%) (As of 05/31/2023 ET) Add Compare Share Share Today's Range$1.12▼$1.3550-Day Range$0.61▼$3.1152-Week Range$0.58▼$12.22Volume12.71 million shsAverage Volume1.75 million shsMarket Capitalization$12.51 millionP/E RatioN/ADividend YieldN/APrice Target$5.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Trevena MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside382.5% Upside$5.50 Price TargetShort InterestBearish7.05% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.30Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.90) to ($1.09) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.85 out of 5 starsMedical Sector762nd out of 1,006 stocksPharmaceutical Preparations Industry382nd out of 492 stocks 3.5 Analyst's Opinion Consensus RatingTrevena has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.50, Trevena has a forecasted upside of 382.5% from its current price of $1.14.Amount of Analyst CoverageTrevena has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.05% of the float of Trevena has been sold short.Short Interest Ratio / Days to CoverTrevena has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Trevena has recently increased by 341.21%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTrevena does not currently pay a dividend.Dividend GrowthTrevena does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TRVN. Previous Next 2.9 News and Social Media Coverage News SentimentTrevena has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Trevena this week, compared to 2 articles on an average week.Search Interest34 people have searched for TRVN on MarketBeat in the last 30 days. MarketBeat Follows8 people have added Trevena to their MarketBeat watchlist in the last 30 days. This is an increase of 700% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Trevena insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.60% of the stock of Trevena is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Trevena are expected to grow in the coming year, from ($2.90) to ($1.09) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Trevena is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Trevena is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTrevena has a P/B Ratio of 1.23. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Trevena (NASDAQ:TRVN) StockTrevena, Inc. is a biopharmaceutical company, which focuses on developing and commercializing novel medicines for patients affected by central nervous system, or CNS, disorders. Its product candidates include Oliceridine injection, TRV250, TRV734, and TRV045. The company was founded by Maxine Gowen, Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin, and Erin Whalen on November 9, 2007 and is headquartered in Chesterbrook, PA.Read More Receive TRVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Trevena and its competitors with MarketBeat's FREE daily newsletter. Email Address TRVN Stock News HeadlinesMay 31, 2023 | finance.yahoo.comTrevena Announces Receipt of Milestone Payment From Partner in China Jiangsu Nhwa PharmaceuticalMay 30, 2023 | markets.businessinsider.comTrevena Achieves Listing Compliance On NasdaqMay 31, 2023 | Legacy Research (Affiliate) (Ad)Sell every Stock except ONE Markets are down...But Jeff Clark couldn't care less because he ignores almost every stock in the market except ONE. He lives financially free trading this One Stock Once per month...May 30, 2023 | finanznachrichten.deTrevena, Inc.: Trevena Regains Compliance with Nasdaq Listing and Reaffirms Expected Near-Term MilestonesMay 30, 2023 | finance.yahoo.comTrevena Regains Compliance with Nasdaq Listing and Reaffirms Expected Near-Term MilestonesMay 27, 2023 | americanbankingnews.comTrevena (NASDAQ:TRVN) Coverage Initiated at StockNews.comMay 21, 2023 | americanbankingnews.comFY2023 EPS Estimates for Trevena, Inc. Increased by Cantor Fitzgerald (NASDAQ:TRVN)May 20, 2023 | americanbankingnews.comTrevena (NASDAQ:TRVN) Now Covered by Analysts at StockNews.comMay 31, 2023 | Legacy Research (Affiliate) (Ad)Sell every Stock except ONE Markets are down...But Jeff Clark couldn't care less because he ignores almost every stock in the market except ONE. He lives financially free trading this One Stock Once per month...May 18, 2023 | msn.comJMP Securities Reiterates Trevena (TRVN) Market Outperform RecommendationMay 17, 2023 | americanbankingnews.comTrevena (NASDAQ:TRVN) Issues Quarterly Earnings ResultsMay 17, 2023 | americanbankingnews.comTrevena (NASDAQ:TRVN) Issues Quarterly Earnings Results, Beats Estimates By $0.04 EPSMay 16, 2023 | markets.businessinsider.comJMP Securities Sticks to Their Buy Rating for Trevena (TRVN)May 14, 2023 | americanbankingnews.comTrevena (TRVN) to Release Earnings on MondayMay 12, 2023 | msn.comTrevena Earnings PreviewMay 12, 2023 | bizjournals.comLab Notes: Trevena receives $3M payment; Wayne firm raises $7.2MMay 12, 2023 | msn.comTrevena Q1 Earnings PreviewMay 11, 2023 | americanbankingnews.comTrevena (NASDAQ:TRVN) Now Covered by StockNews.comMay 11, 2023 | msn.comOliver Trevena Signs First-Look Unscripted Deal With MAK PicturesMay 10, 2023 | theglobeandmail.comTrevena (NASDAQ: TRVN) Partner Receives Approval for OLINVYK in ChinaMay 10, 2023 | msn.comTrevena stock soars toward 5-fold gain in very active trading, after pain treatment gets approved in ChinaMay 10, 2023 | markets.businessinsider.comJMP Securities Keeps Their Buy Rating on Trevena (TRVN)May 10, 2023 | msn.comWhy Trevena Shares Are Skyrocketing TodayMay 10, 2023 | msn.comTrevena Almost Quintuples on Chinese Drug ApprovalMay 9, 2023 | finance.yahoo.comTrevena to Release First Quarter 2023 Financial Results on May 15, 2023May 8, 2023 | finance.yahoo.comTrevena Announces Approval of OLINVYK in ChinaMay 8, 2023 | investorplace.comWhy Is Trevena (TRVN) Stock Up 165% Today?See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive TRVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Trevena and its competitors with MarketBeat's FREE daily newsletter. Email Address TRVN Company Calendar Last Earnings5/15/2023Today5/31/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TRVN CUSIPN/A CIK1429560 Webwww.trevena.com Phone(610) 354-8840FaxN/AEmployees25Year FoundedN/APrice Target and Rating Average Stock Price Forecast$5.50 High Stock Price Forecast$9.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+356.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($6.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-53,670,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-215.90% Return on Assets-88.96% Debt Debt-to-Equity Ratio1.33 Current Ratio3.84 Quick Ratio3.72 Sales & Book Value Annual Sales$570,000.00 Price / Sales23.21 Cash FlowN/A Price / Cash FlowN/A Book Value$0.93 per share Price / Book1.30Miscellaneous Outstanding Shares10,970,000Free Float10,574,000Market Cap$13.23 million OptionableOptionable Beta2.05 Key ExecutivesCarrie L. BourdowPresident, Chief Executive Officer & DirectorBarry ShinChief Financial Officer & Senior Vice PresidentMark A. DemitrackChief Medical Officer & Senior Vice PresidentAngela BagleyVice President-Technical OperationsTodd L. WandstratVice President-Medical AffairsKey CompetitorsFrequency TherapeuticsNASDAQ:FREQBiofronteraNASDAQ:BFRINanoViricidesNYSE:NNVCComera Life SciencesNASDAQ:CMRABio-PathNASDAQ:BPTHView All CompetitorsInsiders & InstitutionsArmistice Capital LLCSold 314,084 shares on 5/16/2023Ownership: 3.424%Jane Street Group LLCBought 28,303 shares on 5/16/2023Ownership: 0.472%Renaissance Technologies LLCBought 24,080 shares on 5/12/2023Ownership: 0.735%Simplex Trading LLCSold 19,200 shares on 4/27/2023Ownership: 0.000%Barry ShinSold 1,271 sharesTotal: $13,027.75 ($10.25/share)View All Insider TransactionsView All Institutional Transactions TRVN Stock - Frequently Asked Questions Should I buy or sell Trevena stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trevena in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TRVN shares. View TRVN analyst ratings or view top-rated stocks. What is Trevena's stock price forecast for 2023? 2 equities research analysts have issued 12-month price objectives for Trevena's stock. Their TRVN share price forecasts range from $2.00 to $9.00. On average, they anticipate the company's stock price to reach $5.50 in the next year. This suggests a possible upside of 356.1% from the stock's current price. View analysts price targets for TRVN or view top-rated stocks among Wall Street analysts. How have TRVN shares performed in 2023? Trevena's stock was trading at $1.43 on January 1st, 2023. Since then, TRVN shares have decreased by 15.7% and is now trading at $1.2059. View the best growth stocks for 2023 here. Are investors shorting Trevena? Trevena saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 752,700 shares, an increase of 341.2% from the April 30th total of 170,600 shares. Based on an average daily trading volume, of 2,500,000 shares, the short-interest ratio is currently 0.3 days. Currently, 7.1% of the company's stock are short sold. View Trevena's Short Interest. When is Trevena's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our TRVN earnings forecast. How were Trevena's earnings last quarter? Trevena, Inc. (NASDAQ:TRVN) released its earnings results on Monday, May, 15th. The biopharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.85) by $0.04. The biopharmaceutical company had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.60 million. During the same period in the prior year, the business posted ($2.50) earnings per share. When did Trevena's stock split? Shares of Trevena reverse split on the morning of Wednesday, November 9th 2022. The 1-25 reverse split was announced on Wednesday, November 9th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What other stocks do shareholders of Trevena own? Based on aggregate information from My MarketBeat watchlists, some companies that other Trevena investors own include Conatus Pharmaceuticals (CNAT), Novavax (NVAX), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Aeterna Zentaris (AEZS), Bionano Genomics (BNGO) and Dynavax Technologies (DVAX). What is Trevena's stock symbol? Trevena trades on the NASDAQ under the ticker symbol "TRVN." Who are Trevena's major shareholders? Trevena's stock is owned by a number of institutional and retail investors. Top institutional investors include Armistice Capital LLC (3.42%), Renaissance Technologies LLC (0.74%), Jane Street Group LLC (0.47%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Barry Shin and Carrie L Bourdow. View institutional ownership trends. How do I buy shares of Trevena? Shares of TRVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Trevena's stock price today? One share of TRVN stock can currently be purchased for approximately $1.21. How much money does Trevena make? Trevena (NASDAQ:TRVN) has a market capitalization of $13.23 million and generates $570,000.00 in revenue each year. The biopharmaceutical company earns $-53,670,000.00 in net income (profit) each year or ($6.04) on an earnings per share basis. How can I contact Trevena? Trevena's mailing address is 955 Chesterbrook Boulevard Suite 110, Chesterbrook PA, 19087. The official website for the company is www.trevena.com. The biopharmaceutical company can be reached via phone at (610) 354-8840 or via email at ir@trevena.com. This page (NASDAQ:TRVN) was last updated on 5/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trevena, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.